Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
暂无分享,去创建一个
R. Greil | J. Bergh | P. Malmström | M. Gnant | S. Loibl | M. Untch | G. Steger | N. Bengtsson | G. Steger | H. Johansson | T. Foukakis | V. Moebus | A. Matikas | H. Johansson | M. Hellstrom | M. Hellström | J. Bergh
[1] J. Bergh,et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials , 2018 .
[2] J. Bergh,et al. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer , 2017, Breast Cancer Research and Treatment.
[3] R. Greil,et al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. , 2016, JAMA.
[4] P. Goodwin,et al. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Denkert,et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] G. Tang,et al. Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[7] M. Beckmann,et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial , 2015, Breast Cancer Research.
[8] Keda Yu,et al. Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women , 2015, PloS one.
[9] A. Schneeweiss,et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials , 2015, Breast Cancer Research and Treatment.
[10] E. Perez,et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer , 2012, Cancer.
[11] G. Rosner,et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Bergh,et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer , 2011, Acta oncologica.
[13] G. Kerr,et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer , 2003, British Journal of Cancer.
[14] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Blomqvist,et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.
[16] A. Goldhirsch,et al. Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .
[18] A. Auvinen,et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. , 1997, British Journal of Cancer.